Vibose 0.2 mg Tablet is an oral antidiabetic medicine containing Voglibose, an alpha-glucosidase inhibitor. It is primarily used to control post-prandial hyperglycaemia (PPHG) in patients with diabetes mellitus when diet, exercise, lifestyle modification, or other antidiabetic therapies alone do not provide adequate glycaemic control. Vibose works locally in the gastrointestinal tract to delay carbohydrate digestion and glucose absorption, thereby reducing post-meal blood glucose spikes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Alpha-Glucosidase Inhibitor

Indications

Vibose 0.2 mg is indicated for:

• Reduction of post-prandial hyperglycaemia in diabetes mellitus

• Non-insulin-dependent diabetes mellitus (NIDDM) as monotherapy

• Use in combination with other oral hypoglycaemic agents

• Adjunct therapy with insulin in diabetes mellitus patients

• Prevention of progression to type 2 diabetes mellitus in patients with impaired glucose tolerance (when diet and exercise alone are insufficient)

• Elderly patients and those with hepatic dysfunction or mild to moderate renal impairment where other OHAs are contraindicated or require caution

• Prevention of hypoglycaemia in patients with glycogen storage disease type Ib

• Management of non-diabetic hyperinsulinaemia to prevent hypoglycaemic episodes

• Steroid-induced diabetes mellitus (clinical data limited)

Pharmacology

Voglibose inhibits intestinal alpha-glucosidase enzymes located in the brush border of the small intestine. These enzymes are responsible for breaking down complex carbohydrates into absorbable monosaccharides. By inhibiting these enzymes, Vibose delays carbohydrate digestion, resulting in reduced glucose absorption after meals. This leads to lower post-prandial blood glucose levels and a modest long-term reduction in HbA1c.

Dosage and Administration

Adults:

• Usual dose: 0.2 mg orally, three times daily, taken immediately before each main meal

• Dose may be increased to 0.3 mg three times daily if required

Geriatric Patients:

• Recommended to start at a lower dose (e.g. 0.1 mg three times daily)

• Careful monitoring of blood glucose and gastrointestinal symptoms is advised

Pediatric Use:

• Safety and efficacy in children have not been established

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Drug Interactions

Use Vibose with caution when administered with:

• Other antidiabetic drugs such as sulfonylureas, biguanides, insulin, and insulin resistance-improving agents

• Drugs that enhance hypoglycaemic effect: beta-blockers, salicylates, MAO inhibitors, fibrates, warfarin

• Drugs that reduce hypoglycaemic effect: adrenaline, corticosteroids, thyroid hormones

Contraindications

Vibose 0.2 mg is contraindicated in patients with:

• Known hypersensitivity to voglibose or any excipients

• Diabetic ketoacidosis or diabetic pre-coma

• Severe infections, major trauma, or peri-operative conditions

• Gastrointestinal obstruction or conditions predisposing to obstruction

Side Effects

Common adverse effects include:

• Diarrhoea, loose stools, abdominal pain, constipation

• Flatulence, nausea, vomiting, heartburn

• Loss of appetite

Rare but serious effects may include:

• Hypoglycaemia (when combined with other OHAs)

• Liver dysfunction, hepatitis, jaundice

• Anaemia, edema, blurred vision, weakness, hyperkalaemia

Pregnancy and Lactation

• Pregnancy: Safety not established; use only if clearly needed

• Lactation: Not recommended due to limited safety data

Precautions and Warnings

• Monitor blood glucose closely when used with other antidiabetic agents

• Use with caution in patients with gastrointestinal disorders, hepatic or renal impairment

• Special care is required in elderly patients

Overdose

Overdose does not usually cause hypoglycaemia. Symptoms may include transient gastrointestinal discomfort such as flatulence, diarrhoea, and abdominal pain. Serious systemic effects are unlikely.

Storage Conditions

Store in a cool and dry place.
Protect from light and keep out of reach of children.